Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Does Apple Inc. (AAPL) Have Too Much Money?

Page 1 of 2

If there is one problem that we all wish we had, it would be to have too much cash. That problem that is at the root of hedge fund star David Einhorn‘s suit against Apple Inc. (NASDAQ:AAPL). The crux of the case is a dispute over how Apple Inc. (NASDAQ:AAPL) should best deploy the staggering stockpile of cash that it has, and continues to, amass. In a recent press release, in addition to trying to clarify its position over the brewing proxy battle, the company references both the $45 billion it is trying to return to investors over the course of three years and the $23 billion in cash flow from operations it generated last quarter. That is correct: quarter, not year. Like I said, it is a problem we’d all like to have.

One of the more interesting aspects of the case is that as the story of Einhorn’s lawsuit broke, shares spiked in late trading ahead of the bell. While it is hard to imagine a company having too much cash, and I applaud Einhorn’s suggestions, the market seems to have remembered that behind the shares that have dropped 35% from their high is a huge pile of money. Not too much, but maybe just enough to get the stock back on track.

Apple Inc. (NASDAQ:AAPL)

What’s Einhorn’s beef?
Einhorn, founder of Greenlight Capital, alleges in his suit that Proposal 2 on Apple Inc. (NASDAQ:AAPL)’s recent proxy statement would “restrict the board’s ability to unlock the value on Apple’s balance sheet.” The hedge fund manager has apparently had several conversations with both CEO Tim Cook and CFO Peter Oppenheimer in which the Apple Inc. (NASDAQ:AAPL) executives were strongly urged to issue preferred shares of Apple stock rather than simply returning cash through a share buyback. He urged Oppenheimer to issue $50 billion of preferred shares that would carry a 4% annual dividend yield; the Apple executive asserted that Einhorn’s calculations were inaccurate and that the shares would carry an 8% dividend under the structure, which was too high.

The matter was finally taken to Cook who, according to Einhorn, was essentially unfamiliar with the issues in play. The company has remained opposed to the suggestion without being hostile. This did not, however, prevent Apple Inc. (NASDAQ:AAPL) from placing Proposal 2 in its proxy statement — the proposal would make shareholder approval a necessary step for the company to issue preferred shares. Rather than heeding the advice of one of its biggest advocates, Apple seems to be seeking to actively block his suggestion.

Apple Inc. (NASDAQ:AAPL) responds
In response to the suit filed in New York’s U.S. District Court, Apple issued a statement in which it tried to clarify its position vis-a-vis the proposal on preferred shares:

Contrary to Greenlight’s statements, adoption of Proposal 2 would not prevent the issuance of preferred stock. Currently, Apple’s articles of incorporation provide for the issuance of “blank check” preferred stock by the Board of Directors without shareholder approval. If Proposal 2 is adopted, our shareholders would have the right to approve the issuance of preferred stock. As such, Proposal 2 has the support of many of our shareholders.

While Einhorn acknowledges that the company would still have the ability to issue preferred shares on a more restrictive basis, he believes that the creation of an “extra hurdle” is unacceptable. So, as so many Americans do when things go the wrong way — meaning contrary to their wishes — Einhorn filed suit. Despite the ongoing discussions with the company, he claims that the pending annual meeting on Feb. 27 is too close to wait any longer.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!